Key points are not available for this paper at this time.
Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune response. In this context, blocking PD-1/PD-L1 could restore T cells from exhausted status and eradicate cancer cells. However, only a subset of PD-L1 positive patients benefits from α-PD-1/PD-L1 therapies. Actually, PD-L1 expression is regulated by various factors, leading to the diverse significances of PD-L1 positivity. Understanding the mechanisms of PD-L1 regulation is helpful to select patients and enhance the treatment effect. In this review, we focused on PD-L1 regulators at the levels of transcription, post-transcription, post-translation. Besides, we discussed the potential applications of these laboratory findings in the clinic.
Building similarity graph...
Analyzing shared references across papers
Loading...
Yi et al. (Thu,) studied this question.
synapsesocial.com/papers/69dab08d4a1e15904c835b98 — DOI: https://doi.org/10.1186/s13045-020-01027-5
Ming Yi
Southwest Medical University
Mengke Niu
Zhejiang Chinese Medical University
Linping Xu
Henan Cancer Hospital
SHILAP Revista de lepidopterología
Journal of Hematology & Oncology
Huazhong University of Science and Technology
Zhengzhou University
Tongji Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: